Lee,
GENE - it was partly Joe and partly this report:
Genome Therapeutics Q2 improves
WALTHAM, Mass., March 22 (Reuters) -
GENOME THERAPEUTICS CORP.
STATEMENTS OF OPERATIONS
(in thousands, except share and per share amounts)
(unaudited)
Thirteen weeks ended Twenty-six weeks ended
Feb. 26, Feb. 27, Feb. 26, Feb. 27,
2000 1999 2000 1999
Revenues:
Contract research, licenses
and subscription fees
& royalties $7,805 $6,403 $ 13,840 $ 11,513
Costs and expenses:
Research and development
6,408 6,673 11,750 13,486
Selling, general
and administrative
1,718 1,152 2,688 2,062
Total costs
and expenses 8,126 7,825 14,438 15,548
Loss from operations
(321) (1,422) (598) (4,035)
Interest income 435 462 799 874
Interest expense (187) (258) (396) (529)
Net loss (73) (1,218) (195) (3,690)
Basic/diluted net loss
per common share
(0.00)* (0.07) (0.01) (0.20)
Basic/diluted weighted
average number of
common shares
outstanding 19,843,446 18,352,272 19,395,565 18,335,058
* rounds to less than ($0.01)
SELECTED BALANCE SHEET DATA
(in thousands) (unaudited)
Feb 26, Aug 31,
2000 1999
Cash, cash equivalents,
restricted cash
and investments $35,891 $25,062
Total assets 51,034 39,485
Long-term obligations,
net of current maturities 5,760 5,925
Shareholders' equity 31,054 23,411
SOURCE Genome
Therapeutics Corp.
-- New York Newsdesk 212 603-3310 |
